Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-07-16 am EDT			5-day change	1st Jan Change
335.80 ^DKK	+1.59%		+4.89%	+3.24%

11:17am	European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday	MT
10:41am	Länsförsäkringar Sverige Vision rose 1.56 percent in June, overweight positions in Essity and Novo Nordisk contributed the most positively	FW

NOVO NORDISK : Goldman Sachs gives a Neutral rating

Published on 06/04/2026 at 06:23 am EDT

MarketScreener with dpa-AFX Analyser

Add MarketScreener to your sources

NOVO NORDISK A/S

+1.59%

In a research note, Goldman Sachs analyst James Quigley has maintained his recommendation on the stock with a Neutral rating. The target price has been raised to DKK 305 from DKK 263.

Add MarketScreener to your sources

Latest news about Novo Nordisk A/S

11:17am	European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday	MT
10:41am	Länsförsäkringar Sverige Vision rose 1.56 percent in June, overweight positions in Essity and Novo Nordisk contributed the most positively	FW
03:06am	Handelsbanken raises its target price for Novo Nordisk to 365 Danish kroner (350), reiterates buy	FW
01:05am	United Laboratories Unit Receives $13.5 Million Milestone Payment From Novo Nordisk	MT
12:49am	Nordic stocks in North America, Autoliv fell 1.6 percent	FW
12:22am	Novo Nordisk: EU approves Wegovy in tablet form	FW
11:34pm	Novo Nordisk Gets Regulatory Nod to Market Weight Loss Pill in EU	MT
Jul. 15	Novo Nordisk Receives European Commission Approval of Wegovy® Pill as First Oral Glp-1 for Weight Management in the Eu; Single, Ready-To-Use Pen for Higher Dose 7.2 Mg Also Approved	CI
Jul. 15	Novo Nordisk Gets EU Approval for Wegovy Pill for Weight Management	MT
Jul. 15	Chip-Machine Supplier ASML Raises Guidance Again on Unrelenting AI Demand -- 5th Update	DJ
Jul. 15	Novo Nordisk wins EU approval for Wegovy weight-loss pill	RE
Jul. 15	Novo Nordisk's Wegovy Pill Gains EU Approval	DJ
Jul. 15	Novo Nordisk: EU green light for the oral version of Wegovy
Jul. 15	European Equities Traded in the US as American Depositary Receipts Advance Wednesday	MT
Jul. 15	India's Sun Pharma wins South Africa approval to launch generic Ozempic	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

67,900

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company